ArcticZymes Technologies (AZT) Aktievy
ArcticZymes Technologies ASA, ett life science-företag, utvecklar, tillverkar och kommersialiserar rekombinanta enzymer för användning inom molekylär forskning, in vitro-diagnostik och biotillverkning i Norge, Tyskland, Litauen, Frankrike, Italien, Storbritannien, övriga Europa, USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
AZT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ArcticZymes Technologies ASA Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | NOK 18.65 |
| 52 veckors högsta | NOK 31.40 |
| 52 veckors lägsta | NOK 16.25 |
| Beta | 0.55 |
| 1 månads förändring | -7.21% |
| 3 månaders förändring | -6.75% |
| 1 års förändring | 13.03% |
| 3 års förändring | -53.26% |
| 5 års förändring | -82.07% |
| Förändring sedan börsintroduktionen | -25.40% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • Apr 27
AZT: Enzyme Platform Expansion And Investor Day Will Support Future Upside
Analysts have slightly reduced their price target on ArcticZymes Technologies from NOK 32.50 to NOK 32.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation (Key Developments).Uppdatering av berättelse • Apr 12
AZT: Enzyme Platform Scaling And Analyst Day Will Support Future Upside
Analysts now keep their price target for ArcticZymes Technologies steady at NOK 32.50, reflecting largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their models. What's in the News ArcticZymes Technologies plans an Analyst/Investor Day to outline how the company has completed its commercial transformation and is now focused on scaling its enzyme platform across biomanufacturing and molecular tool markets (Key Developments).Uppdatering av berättelse • Mar 29
AZT: Enzyme Platform Scaling Across Biomanufacturing And Molecular Tools Will Drive Future Upside
Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.5, noting only minor adjustments to factors such as the discount rate, revenue growth assumptions and future P/E that do not materially affect their overall assessment of fair value. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation.Uppdatering av berättelse • Mar 14
AZT: Enzyme Platform Scaling Across Biomanufacturing Markets Will Support Future Upside
Analysts have slightly adjusted their price target for ArcticZymes Technologies to NOK 32.50, reflecting modest tweaks to their discount rate, revenue growth expectations, profit margin assumptions, and future P/E inputs, while keeping their overall fair value view unchanged. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day to explain how it has completed its commercial transformation.Uppdatering av berättelse • Feb 27
AZT: Enzyme Platform Scaling Across Biomanufacturing Will Drive Future Upside
Analysts have trimmed their price target for ArcticZymes Technologies to NOK 32.5 from NOK 40.20. They cite slightly lower assumptions for long term revenue growth, profit margin and future P/E, along with a modestly higher discount rate in their models.Analysartikel • Feb 15
Results: ArcticZymes Technologies ASA Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, ArcticZymes Technologies ASA ( OB:AZT ) just kicked off its latest full-year results with some very...Uppdatering av berättelse • Feb 13
AZT: Buyback Program And Platform Scaling Will Support Future Upside
Analysts have nudged their price target for ArcticZymes Technologies to NOK32.50 from NOK32.00, reflecting updated views on slightly adjusted revenue growth, profit margin assumptions and a higher future P/E multiple. What's in the News ArcticZymes Technologies plans an Analyst and Investor Day to explain how it has completed its commercial transformation and is now focused on scaling its enzyme platform across high growth biomanufacturing and molecular tool markets (Key Developments).Uppdatering av berättelse • Jan 23
AZT: European Distribution Deal And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for ArcticZymes Technologies steady at NOK 32.0 per share, indicating only minor adjustments in assumptions such as the discount rate and future P/E, rather than any major change in their overall view. What's in the News ArcticZymes Technologies ASA plans to start share repurchases on November 25, 2025, under an AGM mandate from May 27, 2025.Analysartikel • Jan 08
Subdued Growth No Barrier To ArcticZymes Technologies ASA (OB:AZT) With Shares Advancing 25%
Those holding ArcticZymes Technologies ASA ( OB:AZT ) shares would be relieved that the share price has rebounded 25...Uppdatering av berättelse • Jan 07
AZT: European Distribution Agreement And Share Buyback Will Support Future Upside
Analysts have maintained their fair value estimate for ArcticZymes Technologies at $32.0. They cite unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for leaving their price target intact. What's in the News ArcticZymes Technologies ASA started a share repurchase program on November 25, 2025, under an authorization from the May 27, 2025 Annual General Meeting.Analysartikel • Jan 07
Are Investors Undervaluing ArcticZymes Technologies ASA (OB:AZT) By 50%?
Key Insights The projected fair value for ArcticZymes Technologies is kr45.44 based on 2 Stage Free Cash Flow to Equity...Uppdatering av berättelse • Dec 23
AZT: European Distribution Deal And Buyback Program Will Drive Future Upside
Analysts have modestly raised their price target on ArcticZymes Technologies to NOK 32.00, reflecting slightly lower perceived risk and continued confidence in the company’s robust growth and margin profile. What's in the News ArcticZymes Technologies has commenced a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90 percent of outstanding share capital.Uppdatering av berättelse • Dec 09
AZT: European Distribution Deal Will Drive Future Demand And Margin Strength
Narrative Update on ArcticZymes Technologies Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.00, reflecting largely unchanged assumptions on fair value, revenue growth, and profit margins, while only slightly adjusting the discount rate and future price to earnings expectations. What's in the News ArcticZymes Technologies ASA has launched a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90% of outstanding capital, with authorization valid until the 2026 AGM or June 30, 2026, whichever comes first (Key Developments).Uppdatering av berättelse • Nov 25
AZT: Exclusive Distribution Partnership Will Drive European Expansion And Strengthen Margins
Analysts have adjusted their price target for ArcticZymes Technologies, keeping it at NOK 32.00. This decision is based on continued expectations for strong profit margins along with a more cautious perspective on future earnings multiples.Analysartikel • Nov 20
More Unpleasant Surprises Could Be In Store For ArcticZymes Technologies ASA's (OB:AZT) Shares After Tumbling 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...Uppdatering av berättelse • Nov 10
AZT: Exclusive Distribution Deal Will Improve Profitability And European Market Presence
Analysts have maintained their fair value estimate for ArcticZymes Technologies at NOK 32.00, citing stable profit margin improvements and changes in the revenue growth outlook as key factors in their latest assessment. What's in the News ArcticZymes Technologies ASA and Brenntag Specialties Pharma have signed an exclusive distribution agreement for SAN-HQ and M-SAN enzymes across Europe.Uppdatering av berättelse • Oct 27
Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies
Analysts have maintained their fair value price target for ArcticZymes Technologies at NOK 32.00. They cite stable revenue growth and profitability projections as the basis for leaving their outlook unchanged.Uppdatering av berättelse • Oct 13
Biomanufacturing And Gene Therapies Will Expand Precision Medicine
Analysts have raised their price target for ArcticZymes Technologies from NOK 29 to NOK 32. They cite updated growth forecasts and stronger margin expectations as key factors in the upward revision.Uppdatering av berättelse • Aug 15
Biomanufacturing Advances Will Unlock Global Market Access
The significant increase in consensus analyst price target for ArcticZymes Technologies is primarily driven by notably higher forecasts for revenue growth and a rising future P/E multiple, resulting in an upward revision from NOK17.50 to NOK24.50. What's in the News Launched M-SAN HQ GMP, a new GMP-grade nuclease tailored for viral vector manufacturing, enabling high activity in physiological salt conditions and improving DNA removal without harsh buffers.Analysartikel • Aug 15
What ArcticZymes Technologies ASA's (OB:AZT) 50% Share Price Gain Is Not Telling You
ArcticZymes Technologies ASA ( OB:AZT ) shareholders have had their patience rewarded with a 50% share price jump in...Analysartikel • Mar 11
ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up
The ArcticZymes Technologies ASA ( OB:AZT ) share price has done very well over the last month, posting an excellent...Analysartikel • Feb 15
ArcticZymes Technologies ASA's (OB:AZT) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights The projected fair value for ArcticZymes Technologies is kr27.08 based on 2 Stage Free Cash Flow to Equity...
Ny berättelse • Jan 20
Transition To Solution Provider Will Accelerate Market Penetration By Late 2025
ArcticZymes is shifting from raw materials to solutions, aiming for revenue growth through closer customer interactions and market penetration by late 2025.Analysartikel • Nov 28
Take Care Before Jumping Onto ArcticZymes Technologies ASA (OB:AZT) Even Though It's 25% Cheaper
To the annoyance of some shareholders, ArcticZymes Technologies ASA ( OB:AZT ) shares are down a considerable 25% in...Analysartikel • Nov 12
Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Market forces rained on the parade of ArcticZymes Technologies ASA ( OB:AZT ) shareholders today, when the analysts...Analysartikel • Nov 09
ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its...Analysartikel • Aug 31
The Price Is Right For ArcticZymes Technologies ASA (OB:AZT) Even After Diving 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...Analysartikel • Aug 30
ArcticZymes Technologies' (OB:AZT) Solid Earnings May Rest On Weak Foundations
ArcticZymes Technologies ASA's ( OB:AZT ) healthy profit numbers didn't contain any surprises for investors. We think...Analysartikel • Aug 25
ArcticZymes Technologies ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a sad week for ArcticZymes Technologies ASA ( OB:AZT ), who've watched their investment drop 13% to kr21.00...Analysartikel • May 12
Earnings Miss: ArcticZymes Technologies ASA Missed EPS By 17% And Analysts Are Revising Their Forecasts
Last week, you might have seen that ArcticZymes Technologies ASA ( OB:AZT ) released its quarterly result to the...Analysartikel • Feb 08
ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Last week's earnings announcement from ArcticZymes Technologies ASA ( OB:AZT ) was disappointing to investors, with a...Analysartikel • Feb 04
ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its yearly...Analysartikel • Feb 02
Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
When close to half the companies operating in the Biotechs industry in Norway have price-to-sales ratios (or "P/S...Aktieägarnas avkastning
| AZT | NO Biotechs | NO Marknad | |
|---|---|---|---|
| 7D | -1.8% | 0.4% | 0.1% |
| 1Y | 13.0% | 27.2% | 13.5% |
Avkastning vs industri: AZT presterade sämre än Norwegian Biotechs branschen som gav 27.2 % under det senaste året.
Avkastning vs Marknaden: AZT matchade Norwegian marknaden som gav 13.5 % under det senaste året.
Prisvolatilitet
| AZT volatility | |
|---|---|
| AZT Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.7% |
| 10% least volatile stocks in NO Market | 2.8% |
Stabil aktiekurs: AZT s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för Norwegian.
Volatilitet över tid: AZT s veckovolatilitet ( 8% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av Norwegian aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1990 | 51 | Michael Akoh | www.arcticzymes.com |
ArcticZymes Technologies ASA, ett life science-företag, utvecklar, tillverkar och marknadsför rekombinanta enzymer för användning inom molekylär forskning, in vitro-diagnostik och biotillverkning i Norge, Tyskland, Litauen, Frankrike, Italien, Storbritannien, övriga Europa, USA och internationellt. Företaget erbjuder alkaliskt fosfatas för rengöring före Sangersekvensering och nästa generations sekvenseringsprocesser; UNG för användning i virala och andra molekylärdiagnostiska analyser för avlägsnande av kontaminerande dU-DNA; saltaktiva nukleaser för avlägsnande av nukleinsyror vid tillverkning av virala vektorer, rekombinanta proteiner och andra reagenser; samt dubbelsträngspecifika DNaser och därav avledda kit för avlägsnande av dubbelsträngat DNA. Företaget tillhandahåller också DNA/RNA-polymeraser för teknikutveckling inom life science, molekylär diagnostik, NGS och syntetisk biologi, proteinaser för mikrobiologisk diagnostik och vätskebiopsier samt ligaser för sammanfogning av nukleinsyror.
ArcticZymes Technologies ASA Sammanfattning av grunderna
| AZT grundläggande statistik | |
|---|---|
| Börsvärde | NOK 962.70m |
| Vinst(TTM) | NOK 13.43m |
| Intäkter(TTM) | NOK 128.37m |
70.9x
P/E-förhållande7.4x
P/S-förhållandeÄr AZT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| AZT resultaträkning (TTM) | |
|---|---|
| Intäkter | NOK 128.37m |
| Kostnad för intäkter | NOK 6.14m |
| Bruttovinst | NOK 122.23m |
| Övriga kostnader | NOK 108.80m |
| Intäkter | NOK 13.43m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 14, 2026
| Vinst per aktie (EPS) | 0.26 |
| Bruttomarginal | 95.22% |
| Nettovinstmarginal | 10.46% |
| Skuld/egenkapitalförhållande | 0% |
Hur har AZT utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/20 19:49 |
| Aktiekurs vid dagens slut | 2026/07/20 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
ArcticZymes Technologies ASA bevakas av 6 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Carnegie |
| Viktor Sundberg | Nordea Markets |